Direct answer
For IBS, soluble fiber has moderate-certainty guideline support. A short low-FODMAP trial and peppermint oil may help, but their evidence is low or very low. Peppermint has product-specific contraindications, probiotics are strain-specific, and detox cleanses lack reliable benefit evidence.
- ACG recommends soluble fiber such as psyllium, rather than insoluble bran, for global IBS symptoms; it describes fiber as a reasonable first treatment option.
- A structured, time-limited low-FODMAP trial may improve global IBS symptoms; the 2022 review graded its evidence low. Follow elimination with dietitian-guided reintroduction and personalization.
- Enteric-coated peppermint oil may reduce IBS symptoms, but the 2022 meta-analysis graded its evidence very low; reflux and heartburn limit use.
- Probiotics are strain-specific, not a category-wide fix — AGA’s guideline found insufficient evidence for most digestive indications when treated as a generic class.
- Detox cleanses and colon cleansing have no rigorous evidence for gut health and carry documented harm case reports (NCCIH; Acosta & Cash systematic review).
Table of contents
- Evidence summary
- What gut health means
- All forms and types of gut-health interventions
- How digestion and the microbiome work
- Prevention: the daily gut-health foundation
- IBS: evidence-based management
- Supplements with the best evidence
- Risks and all side effects
- All interactions
- Who should avoid self-treatment
- What works and what does not
- Independent evidence and funding review
- Frequently asked questions
- Sources and publishing notes
Evidence summary
| Claim | Evidence | Primary source | Funding / conflict trace | Strength |
|---|---|---|---|---|
| In healthy-adult trials, fiber increased selected fecal bacteria, especially bifidobacteria; alpha-diversity and most fecal short-chain-fatty-acid outcomes did not change. | Systematic review and meta-analysis of randomized trials in healthy adults. | So et al., American Journal of Clinical Nutrition | Review reports no specific funding and no competing interests. Included-trial funding was not separately verified; these are healthy-adult fecal biomarkers, not proven clinical benefits. | Moderate |
| Low-FODMAP diet can improve global IBS symptoms when used as a limited, structured trial. | ACG guideline using GRADE plus a 2022 network meta-analysis of RCTs. | ACG IBS guideline; Black et al. network meta-analysis | ACG reports no financial support but extensive author commercial ties. The network review declares no competing interests; pooled trial funding needs separate review. | Low; ACG recommendation very low |
| Soluble fiber, especially psyllium-type fiber, is preferred over insoluble wheat bran for IBS symptoms. | ACG recommends soluble but not insoluble fiber; BMJ meta-analysis found benefit for fiber, antispasmodics, and peppermint oil. | ACG IBS guideline; Ford et al., BMJ | ACG reports no financial support but extensive author commercial ties. Ford2008 was funded by the American College of Gastroenterology; authors disclosed extensive company consulting/research relationships and Alimentary Health equity. The authors reported working independently of the funder; underlying-trial finances were not all traced. | ACG: moderate certainty; strong recommendation |
| Probiotics are strain-specific; generic “more strains is better” claims are not supported. | AGA guideline found insufficient evidence for most digestive indications; WGO emphasizes strain-specific effects and lists selected strains by condition. | AGA probiotics guideline; WGO probiotics/prebiotics guideline | AGA funded its guideline without outside funding; Bercik and Weizman disclose commercial relationships. WGO strain tables require their own conflict scrutiny. | Mixed |
| Bifidobacterium infantis 35624, B. bifidum MIMBb75, and Lactiplantibacillus plantarum 299v have human IBS trials, but evidence varies by strain and study quality. | Randomized trials and strain-specific reviews show possible benefit; ACG still recommends against routine probiotics for global IBS because evidence is very low and heterogeneous. | Whorwell et al.; Guglielmetti et al.; Ducrotté et al.; NCCIH IBS review | Whorwell reports mixed public/P&G support, P&G employee authors and Alimentary Health ties. Ducrotté is supported by Rosell-Lallemand and Probi AB with supplied products. MIMBb75: Naturwohl Pharma funding is confirmed in the authors’ reply. Authors’ reply | Low–Moderate |
| Peppermint oil can reduce IBS symptoms in some adults, but reflux and heartburn are common practical limits. | 2022 systematic review/meta-analysis plus randomized trial; ACG suggests peppermint oil for global IBS symptoms. | Ingrosso et al. 2022 meta-analysis; Weerts et al.; ACG IBS guideline | Weerts: ZonMw public grant plus Will Pharma capsules and prior-phase funding; author consulting/licensing ties. No funding or conflict statement was located in the 2022 accepted review manuscript; its financial independence and complete pooled-trial finances remain unknown. | Very low in the 2022 review; ACG low |
| Prebiotics did not improve overall IBS symptoms or quality of life; weak subgroup signals vary by type and dose, and inulin can worsen flatulence. | Meta-analysis of 11 RCTs and 729 patients; no trial was low risk of bias in every domain. | NCCIH IBS review; Wilson et al. meta-analysis | Wilson review funded through a Clasado Biosciences doctoral fellowship; authors also disclose other commercial grants. Company reportedly had no review role. NCCIH is a public-health source. Review disclosures | Weak |
| Digestive enzymes work best when matched to a diagnosed digestive problem, such as lactase deficiency or pancreatic exocrine insufficiency. | Human lactase trials show improved lactose digestion; pancreatic enzyme replacement is a medical therapy for pancreatic insufficiency. | lactase replacement trial; lactase comparison trial; PERT review | The 1984 lactase trial acknowledges enzyme donations from SugarLo and G.B. Fermentation Industries; complete funding and author relationships for the lactase trials and PERT review remain unverified. Their findings are indication-specific; this is not evidence for broad digestive-enzyme blends. | Indication-specific |
| Detox cleanses and colon cleansing are not proven gut-health strategies and can be unsafe. | NCCIH says detox/cleanse studies are few and low quality; colonic cleansing systematic review found no rigorous evidence for health promotion and case reports of harms. | NCCIH detox/cleanse fact sheet; Acosta & Cash systematic review | NCCIH is a public-health source. Acosta & Cash report no financial support. Cash chaired the ACG Public Relations Committee, whose members reviewed and approved drafts. | Doesn’t work / safety concern |
Practical Options for Gut Symptoms
Read the practical summary
Discuss tolerable fiber intake, symptom-specific dietary trials and gut-directed care with a clinician or dietitian. Supplements and digestive enzymes need a specific indication; guideline support and evidence certainty vary across these options. The clinical rule is to seek medical evaluation before self-treatment when symptoms include bleeding, weight loss, anemia, fever, persistent vomiting, nighttime diarrhea, or new symptoms later in life.
What gut health means
Gut health is the combined function of digestion, absorption, motility, barrier function, immune signaling, gut-brain communication, and the microbial ecosystem living mostly in the colon. WGO’s diet-and-gut guideline frames diet as a major driver of gastrointestinal physiology because food interacts directly with digestion, fermentation, immune signaling, and symptoms (WGO Diet and the Gut guideline).
The gut microbiome is a microbial community. Fiber trials measure selected fecal bacteria and metabolites; these biomarkers do not constitute a complete validated gut-health score or establish a clinical benefit on their own (So et al., WGO probiotics/prebiotics guideline).
IBS is now commonly understood as a disorder of gut-brain interaction, meaning pain sensitivity, motility, microbiota, immune activation, diet triggers, and stress responsiveness can all contribute without implying that symptoms are imaginary (ACG guideline, NCCIH IBS review).
All forms and grades
| Type | Examples | Best fit | Evidence grade | Key caveat |
|---|---|---|---|---|
| Dietary fiber from foods | Legumes, oats, barley, vegetables, fruit, nuts, seeds, whole grains. | General prevention, constipation tendency, microbiome substrate. | Moderate for microbiome markers; strong general nutrition rationale. | Increase gradually because rapid change can worsen gas and bloating. |
| Soluble fiber supplements | Psyllium/ispaghula, partially hydrolyzed guar gum, beta-glucan. | IBS-C or mixed IBS, stool normalization, LDL support. | ACG: moderate certainty with a strong recommendation for soluble fiber. | Must be taken with enough fluid and separated from medicines. |
| Fermented foods | Yogurt with live cultures, kefir, fermented vegetables, tempeh, miso, sourdough. | Food diversity and cultural dietary pattern. | Limited for most GI disease outcomes; promising but food-specific. | Fermented food is not the same as a tested probiotic strain. |
| Low-FODMAP diet | Short elimination, structured reintroduction, personalization. | IBS with meal-triggered bloating, pain, diarrhea, or mixed symptoms. | Low in the 2022 review; ACG conditional recommendation with very low certainty. | Not meant as a permanent broad restriction; dietitian support is preferred. |
| Probiotics | B. infantis 35624, B. bifidum MIMBb75, L. plantarum 299v, S. boulardii for antibiotic-associated diarrhea contexts. | Strain-specific trial when the strain matches the outcome. | Mixed for IBS; moderate for some antibiotic-associated diarrhea prevention evidence. | Do not generalize one strain’s evidence to another label. |
| Prebiotics | Inulin, fructooligosaccharides, galactooligosaccharides, resistant starch. | Microbiome feeding and selected constipation/gas outcomes. | Mixed in IBS. | Inulin-type fructans can worsen flatulence in IBS. |
| Peppermint oil | Enteric-coated capsules standardized for menthol-rich oil. | IBS pain/spasm in adults without reflux-prone symptoms. | Very low in the 2022 meta-analysis; ACG conditional recommendation with low certainty. | Can worsen heartburn and should not be used like peppermint tea. |
| Digestive enzymes | Lactase, alpha-galactosidase, pancreatic enzyme replacement therapy, enzyme blends. | Lactose intolerance, bean-related gas, or diagnosed pancreatic insufficiency. | Indication-specific. | Broad enzyme blends are often overmarketed and poorly tested. |
| Gut-brain therapies | Gut-directed CBT, hypnotherapy, mindfulness, relaxation, sleep interventions. | IBS pain, stress-reactive symptoms, symptom fear/avoidance. | ACG conditional recommendation with very low certainty; effects vary by protocol. | Works best as symptom regulation, not as a “stress caused everything” explanation. |
| Cleanses/detoxes | Juice cleanses, colon hydrotherapy, laxative detoxes, coffee enemas. | No routine gut-health role. | Unsupported. | Can cause dehydration, electrolyte problems, infection, or injury. |
How digestion and the microbiome work
Digestion breaks food into absorbable nutrients in the mouth, stomach, small intestine, pancreas, liver-bile system, and colon. The small intestine handles most nutrient absorption, while the colon absorbs water and electrolytes and hosts much of the microbial fermentation of carbohydrates that escaped small-intestinal digestion.
Dietary fibers can reach the colon and be fermented by gut microbes into metabolites including short-chain fatty acids. Human fiber trials show changes in selected fecal bacteria, while diversity and metabolite results vary by fiber and study; these biomarkers do not by themselves prove a clinical benefit (So et al., Makki et al., Cell Host & Microbe review (2018)).
For the Makki review, the original financial disclosures name public and charitable support, including the Novo Nordisk Foundation. Jens Walter discloses research funding from companies that manufacture or market prebiotics and dietary fibers, and co-ownership of Synbiotics Solutions; Fredrik Bäckhed discloses founding and holding shares in Metabogen AB. These author relationships do not establish the financing of every study discussed in the review, and the mechanistic review does not prove a clinical benefit from a particular supplement (Makki et al., original review).
FODMAPs are fermentable carbohydrates that can pull water into the bowel and produce gas through fermentation, which explains why they can trigger pain, bloating, diarrhea, or urgency in susceptible IBS patients (NIDDK IBS diet guidance, AGA diet update).
IBS involves gut–brain signaling, and psychological treatments can address symptom-related anxiety, avoidance and pain coping. In Axelsson et al., exposure therapy and hypnotherapy showed added benefit over attention controls in a time-adjusted analysis, but only exposure retained significance after further adjustment; this was within-group meta-regression, not a direct head-to-head trial. Swedish public/charitable funding supported the review, and two authors own a company licensing exposure-based IBS treatment (psychological treatments meta-analysis, NCCIH IBS review).
Prevention: the daily gut-health foundation
1. Build fiber slowly, not suddenly
A fiber-rich diet is the most defensible everyday microbiome strategy because fiber provides microbial substrate and supports stool form, but rapid increases can worsen bloating. A practical progression is to add one fiber-rich food or a small psyllium dose at a time, then increase only after symptoms stabilize.
2. Use plant diversity as a food pattern, not a supplement claim
Different fibers feed different microbial groups, so a varied dietary pattern is more rational than relying on one “superfood.” The evidence is strongest for dietary pattern consistency and soluble fiber in IBS, not for expensive microbiome-personalized supplements.
3. Keep fermented foods in perspective
Fermented foods can be valuable foods, but a 2019 review found that clinical GI evidence was limited for many fermented foods and that kombucha, miso, kimchi, and tempeh lacked RCTs for gastrointestinal health at that time (Dimidi et al.). Publication was supported by a Danone educational grant to ESNM; authors disclosed food/probiotic-company fees and research support. A later kombucha controlled study was funded by a kombucha company and involved an author on that company’s scientific advisory board, so it should not be used as independent proof of kombucha gut-health claims (kombucha clinical study).
4. Move, sleep, and regulate stress physiology
Gut-directed CBT or hypnotherapy can be considered for IBS symptoms, including symptom fear and avoidance. ACG suggests gut-directed psychotherapy with very-low-certainty evidence. The 2023 psychological treatments meta-analysis found its clearest adjusted signal for exposure-based treatment and called for direct randomized comparisons (ACG guideline, psychological treatments meta-analysis).
Low-FODMAP Is a 3-Phase Test, Not a Lifetime Diet
Read the practical summary
The low-FODMAP diet has three phases: remove high-FODMAP foods for a short symptom test, reintroduce FODMAP groups one at a time, and personalize the diet by keeping tolerated foods. The success measure is less pain, bloating, urgency, or diarrhea while preserving the broadest tolerated diet.
IBS: evidence-based management
IBS management starts by confirming that the symptom pattern fits IBS and that alarm features are absent. ACG supports a positive diagnostic strategy rather than endless exclusion testing, while still recommending celiac testing in IBS with diarrhea symptoms and inflammatory markers such as fecal calprotectin when inflammatory bowel disease is a concern (ACG guideline).
Low-FODMAP diet
ACG recommends a limited trial of a low-FODMAP diet for IBS global symptoms, and AGA’s diet update describes the low-FODMAP diet as one of the best-supported dietary treatments for IBS when implemented thoughtfully (ACG guideline, AGA diet update). The most common mistake is staying in the strict elimination phase too long, which can reduce food variety and make eating unnecessarily restrictive.
Soluble fiber
ACG recommends soluble fiber, but not insoluble fiber, for global IBS symptoms; this matters because wheat bran can worsen symptoms in some people, while psyllium is viscous, soluble, and less fermentable than many prebiotic fibers (ACG guideline, BMJ meta-analysis). Psyllium can be considered for IBS symptoms, including constipation or variable stool form; individual tolerance matters.
Peppermint oil
Peppermint oil acts mainly as an antispasmodic through L-menthol effects on intestinal smooth muscle calcium channels, and meta-analyses show benefit for global IBS symptoms or pain in some adults (peppermint oil meta-analysis, peppermint physiology and safety review). Enteric-coated capsules matter because non-enteric peppermint can worsen reflux and release too early.
Probiotics
Probiotic evidence is not a yes/no category. NCCIH notes that some probiotics may improve IBS symptoms but benefits are not conclusively demonstrated and not all probiotics have the same effects, while ACG recommends against routine probiotic use for global IBS symptoms because evidence quality is very low (NCCIH IBS review, ACG guideline). WGO’s 2023 probiotic guideline lists strain-specific IBS evidence for B. bifidum MIMBb75 and L. plantarum 299v, so a time-limited strain-matched trial is more defensible than a generic multi-strain product (WGO probiotics/prebiotics guideline).
Gut-directed therapy
ACG suggests gut-directed psychotherapy for global IBS symptoms. Options include CBT-based and gut-focused hypnotherapy protocols, but the evidence differs by treatment and study design. The 2023 psychological treatments meta-analysis particularly favored exposure-based therapy after adjustment and cannot establish that every protocol is effective (ACG guideline, psychological treatments meta-analysis).
Supplements with the best evidence
| Supplement | Best-supported use | Typical evidence-based way to use | What not to claim | Safety headline |
|---|---|---|---|---|
| Psyllium / ispaghula | IBS symptoms, constipation tendency, stool form normalization. | Start low, increase gradually, take with a full glass of water, and separate from medicines. | Not a detox binder; not a cure for inflammatory bowel disease, celiac disease, or colon cancer risk. | Gas, bloating, choking/obstruction risk if taken dry or with too little fluid. |
| Enteric-coated peppermint oil | IBS pain, cramping, spasm, bloating in adults without reflux-prone symptoms. | Use product directions from tested enteric-coated formulations; reassess after a defined trial. | Not for chronic unexplained abdominal pain without diagnosis; peppermint tea is not equivalent. | Heartburn, reflux and anal burning. The EMA oral-oil monograph contraindicates use in liver disease, cholangitis, achlorhydria, gallstones and other biliary disorders. |
| Specific probiotics | Selected outcomes: B. bifidum MIMBb75 or L. plantarum 299v for IBS trials; S. boulardii for antibiotic-associated diarrhea prevention evidence. | Choose a named strain studied for the same outcome and trial it for a defined period. | “50 billion CFU” and “15 strains” are not evidence by themselves. | Usually mild GI effects, but infection/fungemia risk exists in vulnerable people. |
| Prebiotics | Microbiome substrate and selected constipation/gas outcomes. | Start at low dose; avoid aggressive inulin loading in IBS. | Not automatically better than dietary fiber; not always IBS-friendly. | Gas, bloating, cramps, diarrhea; high doses can worsen IBS flatulence. |
| Lactase | Lactose maldigestion and lactose-triggered symptoms. | Use with lactose-containing foods; response depends on dose and lactose load. | Does not treat milk allergy, celiac disease, IBS unrelated to lactose, or pancreatic insufficiency. | Generally well tolerated; persistent symptoms need evaluation. |
| Alpha-galactosidase | Gas from beans and alpha-galactoside-rich foods; evidence in IBS bloating is mixed. | Use with trigger meals, not as a daily cure-all. | Does not digest lactose or gluten and does not prove “enzyme deficiency.” | Usually mild; caution in complex diabetes care because products may alter carbohydrate digestion. |
| Pancreatic enzymes | Diagnosed exocrine pancreatic insufficiency. | Prescription-style therapy matched to meals under clinician supervision. | Not a wellness enzyme for ordinary bloating. | High-dose risks and disease-specific monitoring apply. |
Gut Supplement Options and Limits
Read the practical summary
For IBS, ACG supports soluble fiber with moderate certainty. Low-FODMAP evidence is low and peppermint evidence very low; both need indication-specific use. Lactase targets lactose intolerance, while probiotic effects depend on the strain and condition. Fermentable prebiotics can worsen symptoms, and detox or cleanse claims lack reliable benefit evidence.
Risks and all side effects
| Intervention | Common side effects | Uncommon or serious risks | Higher-risk groups | Evidence source |
|---|---|---|---|---|
| Psyllium | Gas, bloating, abdominal fullness, stool changes. | Current psyllium labeling warns of choking or throat/esophageal blockage with inadequate fluid and allergy to ingested or inhaled psyllium. | Swallowing disorders, bowel narrowing/obstruction history, severe constipation with impaction, people who cannot maintain fluid intake. | DailyMed psyllium label |
| Peppermint oil | Heartburn, reflux, peppermint taste/burps, nausea, anal burning. | Reflux worsening, gallbladder symptom concern, rare allergic reactions; non-enteric products can irritate the upper GI tract. | Reflux or hiatal hernia can worsen. The EMA oral-oil monograph contraindicates liver disease, cholangitis, achlorhydria, gallstones and other biliary disorders; oral use below age eight is not recommended. | peppermint physiology and safety review; Weerts trial |
| Probiotics | Gas, bloating, mild GI upset, transient stool changes. | Bacteremia, fungemia, sepsis, and severe or fatal infections have been reported in vulnerable groups, including premature infants. | Serious illness, impaired immunity and premature infancy require specialist review. The S. boulardii CNCM I-745 product label specifically contraindicates central venous catheters, critical illness and immunodeficiency. | NCCIH probiotics safety; NCCIH IBS review |
| Prebiotics | Flatulence, bloating, cramps, abdominal pain, diarrhea. | Symptom flares in IBS, especially with high-dose inulin-type fructans. | People whose symptoms worsen with fermentable fibers should review type and dose with a clinician or dietitian, especially during a structured low-FODMAP trial. | NCCIH IBS review; prebiotic meta-analysis |
| Lactase | The cited trials measured lactose digestion and tolerance; they do not establish safety for every age or formulation. | Persistent symptoms despite lactase may indicate another condition, not “needing more enzyme.” | Milk allergy, unexplained weight loss, persistent diarrhea, anemia, children with growth issues. | lactase replacement trial; lactase comparison trial |
| Alpha-galactosidase | Abdominal pain and diarrhea were more frequent reasons for withdrawal in one IBS trial. | 125 patients over 12 weeks: 18 active versus 7 placebo withdrawals; routine IBS benefit was not established. Allergy is a labeled stop-use reason. | Ask a clinician first with diabetes or pregnancy/breastfeeding; seek review for persistent or worsening symptoms. | IBS alpha-galactosidase trial; Health Canada monograph |
| Pancreatic enzymes | Abdominal pain or stool changes; mouth irritation can occur if enteric-coated capsules are chewed. | CREON labeling warns about rare fibrosing colonopathy, particularly high-dose/prolonged use in children with cystic fibrosis, hyperuricemia and allergic reactions. | Clinician-managed pancreatic insufficiency; additional monitoring with gout, renal disease, prior bowel strictures or pork-protein allergy. | DailyMed CREON prescribing information |
| Detoxes, juice cleanses, colon cleanses | Hunger, diarrhea, cramps, dizziness, dehydration. | Electrolyte imbalance, infection, kidney stone risk from high-oxalate juices, bowel injury/perforation, delayed care. | Kidney disease, heart disease, diabetes, GI disease, pregnancy, older adults, immunocompromised people. | NCCIH detox/cleanse fact sheet; colonic cleansing review |
All interactions
| Intervention | Interacts with | Type / mechanism | Severity | Action |
|---|---|---|---|---|
| Psyllium | Oral medicines including thyroid hormone, lithium, carbamazepine, digoxin, some antidepressants, diabetes medicines, and supplements. | Bulk fiber can delay or reduce absorption of co-ingested medicines; fiber may also modestly affect glucose response. | Use with caution. | Separate medicines from psyllium unless a clinician gives different instructions; monitor glucose if diabetes medications are adjusted. |
| Peppermint oil | Antacids, PPIs, H2 blockers, reflux-prone conditions. | Acid suppression or antacids may affect enteric coating release; peppermint can lower LES tone and worsen reflux symptoms. | Use with caution / avoid in severe reflux. | Stop if heartburn worsens and seek advice. The EMA oral-oil monograph advises avoiding acid-suppressing medicines with gastro-resistant capsules because their coating may dissolve prematurely. |
| Peppermint oil | Cyclosporine and narrow-therapeutic-index drugs. | A 2002 rat study found increased cyclosporine exposure with peppermint oil. Its mechanism and relevance at human clinical doses remain uncertain; this is not a confirmed clinical interaction. | Monitor / clinician-guided. | Do not combine with transplant or narrow-therapeutic-index medicines without prescriber approval. |
| Probiotics | Antibiotics. | Antibiotics can kill susceptible bacterial probiotic strains; probiotic effects may be reduced. | Timing issue. | Separate dosing during an antibiotic course if a clinician recommends probiotic use. |
| Saccharomyces boulardii | Systemic or oral antifungals. | The ANSM label for S. boulardii CNCM I-745 says not to combine this licensed product with oral or systemic antifungals. | This label contraindicates central venous catheters, critical illness and immunodeficiency because of fungemia risk. | Avoid self-use in immunocompromised or central-line patients. |
| Prebiotics | Low-FODMAP elimination, laxatives, diabetes medications. | Fermentable prebiotics can counteract low-FODMAP symptom testing; added fiber can alter stool frequency and post-meal glucose. | Use with caution. | Do not add high-dose inulin during low-FODMAP elimination; start low and monitor symptoms. |
| Lactase | Lactose-containing foods. | Therapeutic food-enzyme interaction; lactase hydrolyzes lactose into simpler sugars. | Usually low. | Use only for lactose exposure; persistent symptoms require evaluation. |
| Alpha-galactosidase | Acarbose; effects with miglitol or other diabetes regimens are not established by the cited trial. | A small Bayer-authored trial found less gas but some attenuation of acarbose’s post-meal glucose-lowering effect. | Use with caution. | Ask the prescribing clinician; monitor glucose if they approve combination use. (Lettieri & Dain) |
| Pancreatic enzymes | Prescription digestive disease regimens. | Dose must match fat intake and pancreatic insufficiency severity; unsupervised use can obscure diagnosis. | Clinician-guided. | Use for diagnosed pancreatic insufficiency, not casual bloating. |
| Colon cleanses / laxative detoxes | Medicines affected by dehydration or electrolyte changes; the cited sources do not establish every drug-specific interaction. | Fluid shifts, diarrhea, and electrolyte changes can amplify medicine toxicity or reduce control of heart rhythm, blood pressure, seizures, or mood disorders. | Avoid unless medically prescribed. | Do not use cleanses for wellness; medical bowel preparation should follow clinician instructions. |
Before Supplements: Check Red Flags
Read the practical summary
Red flags before gut supplements include blood in stool or black stool, unintentional weight loss, iron deficiency or anemia, fever, persistent vomiting, nighttime diarrhea, a new major change in bowel habit, family history of inflammatory bowel disease or colorectal cancer, trouble swallowing, dehydration, or severe pain. These signs do not diagnose a disease, but they make self-treatment the wrong first step.
Who should avoid self-treatment
People with GI bleeding, black stools, anemia, unintentional weight loss, persistent fever, severe dehydration, progressive swallowing trouble, persistent vomiting, nighttime diarrhea, or new unexplained bowel changes should seek medical evaluation before using gut-health supplements. ACG’s IBS guideline supports targeted testing when symptoms suggest celiac disease or inflammatory bowel disease rather than assuming every symptom is IBS (ACG guideline).
People who are immunocompromised, critically ill, premature infants, have central venous catheters, or have severely disrupted intestinal barriers should not self-prescribe probiotics because NCCIH notes severe or fatal infections have been reported in premature infants and serious complications have occurred in people with underlying health problems (NCCIH probiotics safety).
Peppermint oil can worsen heartburn or hiatal-hernia symptoms. The EMA monograph contraindicates gastro-resistant oral peppermint oil in liver disease, cholangitis, achlorhydria, gallstones and other biliary disorders; product instructions and clinician advice matter (EMA oral-oil monograph) (peppermint safety review).
What works and what does not
| Claimed benefit | Verdict | Evidence | Key caveat |
|---|---|---|---|
| “Improve gut health” through more fiber-rich foods. | WORKS as a foundation. | Fiber interventions can shift microbiota composition and soluble fiber is guideline-supported for IBS symptoms (So et al., ACG guideline). | Increase slowly and tailor to IBS/FODMAP tolerance. |
| Low-FODMAP for IBS. | WORKS for many IBS patients. | ACG recommends a limited trial, and a network meta-analysis supports symptom improvement (ACG guideline, Black et al.). | Use as a test-and-reintroduce protocol, not permanent restriction. |
| Psyllium for IBS/constipation pattern. | WORKS. | ACG recommends soluble fiber; psyllium has better rationale than insoluble bran (ACG guideline). | Must be taken with fluid and separated from medicines. |
| Peppermint oil for IBS pain/spasm. | WORKS / MIXED. | The 2022 meta-analysis favored benefit but graded its evidence very low; in its low-bias subset global benefit was not significant. The Weerts trial found no significant primary-endpoint benefit, although some secondary outcomes improved (peppermint meta-analysis, Weerts trial). | Best for selected adults; stop if reflux worsens. |
| Any probiotic for any digestive symptom. | DOESN’T. | NCCIH and WGO emphasize strain-specific effects, and ACG recommends against routine probiotics for global IBS symptoms (NCCIH IBS review, WGO probiotics/prebiotics guideline). | A named strain may still be reasonable for a named outcome. |
| Prebiotics for IBS. | Weak / mixed. | Wilson et al. found no overall symptom or QoL benefit. Low-dose/non-inulin subgroup signals were weak; inulin worsened flatulence. The review had direct Clasado prebiotic-company funding (Wilson et al., NCCIH IBS review). | Start low; avoid during strict low-FODMAP testing. |
| Lactase for lactose intolerance. | WORKS when lactose is the trigger. | Human enzyme trials show reduced breath hydrogen and improved lactose digestion (lactase trial, comparative lactase trial). | Does not treat milk allergy or non-lactose IBS triggers. |
| Alpha-galactosidase for bean-related gas. | MIXED / INDICATION-SPECIFIC. | A meal-challenge trial showed reduced gas production, but an IBS trial did not establish broad symptom relief for everyone (gas-production trial, IBS alpha-galactosidase trial). | Use for specific food-trigger gas, not as a daily IBS cure. |
| Digestive enzyme blends for ordinary bloating. | INSUFFICIENT EVIDENCE. | Enzyme evidence is strongest when a specific enzyme deficiency or pancreatic disease is present (PERT review). | Broad blends can delay diagnosis of celiac disease, IBD, pancreatic insufficiency, or other disorders. |
| Detox, juice cleanse, or colon cleanse for gut reset. | DOESN’T WORK and may harm. | NCCIH says detox studies are few and low quality, and colonic cleansing review found no rigorous support for health promotion (NCCIH detox/cleanse fact sheet, Acosta & Cash). | Risk rises with GI disease, kidney disease, heart disease, diabetes, or immune compromise. |
Independent evidence and funding review
Research funding at a glance
9 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
| Source | Country / organization type | Independence rating | Credibility rank | Likely motivation | How used |
|---|---|---|---|---|---|
| ACG IBS guideline | United States professional society guideline. | Financial support: none reported; authors disclose extensive commercial consulting, research support and equity. Clinical guidance is not an independent-only efficacy synthesis. | Strong. | Standardize evidence-based IBS care and maintain clinical credibility. | Core IBS diagnostic, low-FODMAP, fiber, peppermint, probiotic, and gut-directed psychotherapy verdicts. |
| AGA diet update | United States professional society expert review. | Expert review with no formal evidence grading. Chey and Chang disclose commercial consulting and ModifyHealth stock/options; separate article funding not identified. | Moderate | Give clinicians practical diet guidance for a high-demand IBS topic. | Low-FODMAP and dietitian-guided personalization. |
| WGO probiotics/prebiotics guideline | Global professional organization. | Useful but not fully independent for commercial strain claims because probiotic field experts can have industry relationships. | Moderate–Strong. | Provide global practice guidance and strain-specific education. | Strain-specific caution and probiotic terminology. |
| NCCIH probiotics safety | United States public-health agency. | U.S. government guidance; complete finances of the underlying studies were not traced here. | Very strong for safety. | Reduce consumer harm and communicate evidence limits. | Probiotic safety and uncertainty statements. |
| Low-FODMAP network meta-analysis | UK academic authors; primary manuscript and disclosures reviewed. | No support for this review or relevant conflicts declared. Included-trial funding was not separately verified. | Low GRADE certainty. | Academic synthesis of comparative dietary evidence. | Low-FODMAP efficacy. |
| B. infantis 35624 trial | UK trial; UK/US/Ireland academic and company authors. | Mixed public/P&G support; P&G employees and Alimentary Health company ties; P&G prepared the product. | Weak / conflicted | Establish strain-specific efficacy for IBS. | Used only as strain-specific evidence, not as proof for all probiotics. |
| Kombucha controlled study | Academic/company-linked clinical study. | Conflicted: funded by GT’s Living Foods LLC; one author was on the company scientific advisory board. | Downgraded. | Study a commercial fermented-food category with company relevance. | Used only to show why fermented-food claims need conflict checks. |
| NCCIH detox/cleanse fact sheet | United States public-health agency. | U.S. government guidance; complete finances of the underlying studies were not traced here. | Very strong for consumer safety. | Prevent harm from unsupported health practices. | Detox/cleanse verdict and safety warnings. |
Frequently asked questions
What is the fastest evidence-based way to improve gut health?
A practical starting point is to identify the symptom pattern, increase tolerable fiber gradually, hydrate, regularize meals, move daily, and remove obvious triggers only long enough to test them. If symptoms fit IBS, ACG-supported options include a limited low-FODMAP trial, soluble fiber, peppermint oil, and gut-directed psychotherapy depending on the symptom profile (ACG guideline).
Is low-FODMAP good for the microbiome?
Low-FODMAP can reduce IBS symptoms, but it is not meant to maximize microbiome diversity forever because it temporarily restricts many fermentable plant foods. The goal is symptom control followed by reintroduction and personalization, which is why ACG recommends a limited trial rather than a permanent broad restriction (ACG guideline, AGA diet update).
Which probiotic is best for IBS?
No probiotic is best for every IBS patient. WGO lists strain-specific evidence for options such as B. bifidum MIMBb75 and L. plantarum 299v, while ACG recommends against routine probiotics for global IBS symptoms because the overall evidence is heterogeneous and very low quality (WGO probiotics/prebiotics guideline, ACG guideline).
Does psyllium help IBS?
Psyllium is a reasonable nonprescription IBS option because ACG recommends soluble fiber. Increase gradually. The DailyMed psyllium label requires at least 8 ounces of fluid per dose and warns against use with swallowing difficulty; chest pain, vomiting, or difficulty swallowing or breathing after a dose need immediate medical attention. Separate it from other drugs by at least 2 hours unless their instructions require longer (ACG guideline, DailyMed psyllium label).
Is peppermint oil safe for IBS?
Enteric-coated peppermint oil may help IBS pain or spasm in some adults, but the 2022 review graded its evidence very low. Heartburn, reflux, peppermint burps, nausea and anal burning can occur. The EMA oral-oil monograph contraindicates liver disease, cholangitis, achlorhydria, gallstones and other biliary disorders, and advises avoiding acid-suppressing medicines with gastro-resistant capsules. Reflux or hiatal-hernia symptoms can worsen; stop and seek advice if they do (peppermint meta-analysis, peppermint safety review).
Do digestive enzymes help bloating?
Digestive enzymes help when matched to a specific problem, such as lactase for lactose intolerance or pancreatic enzymes for diagnosed pancreatic insufficiency. Broad enzyme blends for ordinary bloating have weaker evidence and can delay evaluation for IBS, celiac disease, inflammatory bowel disease, pancreatic disease, or food intolerance (lactase trial, PERT review).
Are fermented foods the same as probiotics?
No. Fermented foods can contain live microbes, but WGO says the term probiotic should be reserved for live microbes shown in controlled human studies to confer a health benefit. A fermented food is a food pattern choice; a probiotic is a tested strain-and-dose intervention (WGO probiotics/prebiotics guideline).
Do gut detoxes work?
No good evidence supports detoxes, juice cleanses, or colon cleanses as gut-health resets. NCCIH says detox studies in people are few and low quality, and a clinical systematic review found no rigorous evidence supporting colonic cleansing for general health promotion (NCCIH detox/cleanse fact sheet, Acosta & Cash).
Sources and publishing notes
- Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021.
- Chey WD, Hashash JG, Manning L, Chang L. AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome. Gastroenterology. 2022.
- Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022.
- Su GL, Ko CW, Bercik P, et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020.
- World Gastroenterology Organisation. Probiotics and Prebiotics Global Guideline. 2023.
- World Gastroenterology Organisation. Diet and the Gut Guideline. 2018.
- NCCIH. Probiotics: Usefulness and Safety.
- NCCIH. Irritable Bowel Syndrome and Complementary Health Approaches.
- NIDDK. Eating, Diet, & Nutrition for Irritable Bowel Syndrome.
- So D, Whelan K, Rossi M, et al. Dietary fiber intervention on gut microbiota composition in healthy adults. Am J Clin Nutr. 2018.
- Dimidi E, Cox SR, Rossi M, Whelan K. Fermented Foods: Definitions and Characteristics, Impact on the Gut Microbiota and Effects on GI Health and Disease. Nutrients. 2019.
- Updated systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. PubMed record.
- Review article: The physiologic effects and safety of peppermint oil and its efficacy in IBS and other functional disorders.
- Whorwell PJ, et al. Bifidobacterium infantis 35624 in women with IBS. Am J Gastroenterol. 2006.
- Guglielmetti S, et al. Bifidobacterium bifidum MIMBb75 in IBS. Aliment Pharmacol Ther. 2011.
- Ducrotté P, et al. Lactobacillus plantarum 299v in IBS. World J Gastroenterol. 2012.
- Wilson B, Rossi M, Dimidi E, Whelan K. Prebiotics in IBS and functional bowel disorders. Am J Clin Nutr. 2019.
- Lactase enzyme replacement trial for adult lactase deficiency. PubMed.
- Di Stefano M, et al. Oral alpha-galactosidase and gas production. Dig Dis Sci. 2007.
- Acosta RD, Cash BD. Clinical effects of colonic cleansing for general health promotion. Am J Gastroenterol. 2009.
- NCCIH. “Detoxes” and “Cleanses”: What You Need To Know.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.